Make faster, better drug development decisions
Cancer vaccines have re-emerged as a promising therapeutic option. Advancements in personalized approaches, delivery systems and antigen selection platforms present new opportunities for the development of effective cancer vaccines. The recent potential seen in mRNA-based vaccines has only added to this.
Keeping track of such a broad and varied landscape can be a challenge. Beacon Cancer Vaccine provides the solution you need, allowing you to focus on your research.
Beacon Cancer Vaccine
Track the cancer vaccine-related clinical trial and drug landscape with Beacon Cancer Vaccine
What we cover
Beacon Cancer Vaccine covers trial and drug records for clinical, preclinical, approved and discontinued prophylactic and therapeutic cancer vaccines. This database will cover ‘off the shelf’ and personalized approaches to:
- Cellular Vaccines
- Viral Vaccines
- Bacterial Vaccines
- Protein Vaccines
- Yeast Vaccines
- Peptide Vaccines
- Nucleic Acid-Based Vaccines
Commercial intelligence data expansion: Gain unparalleled access to in-depth company profiles and the latest commercial deals. Monitor your competitors and opportunities as well as benchmark deals and evaluate potential partners. Learn more by downloading the factsheet.
How Beacon helps
Here are some examples of how Beacon Cancer Vaccine can accelerate your research programs:
- Search for Cancer Vaccine drugs across all stages of development so you can accurately benchmark your strategies against other preclinical and clinical drugs, and investigate the novel approaches used by competitors.
- Drastically reduce time spent looking through publications and conference abstracts for clinical trial results by relying on our comprehensive collection of data which can be searched by disease, combination treatments and much more.
- Stay on top of emerging trends and new players in the field with real-time updates and alerts, as well as in-depth monthly reports curated by our expert analyst team.
How Beacon Cancer Vaccine works
Search the trial and drug landscape by antigen, vaccine type and adjuvant alongside other search criteria including disease, biomarker and sponsor to instantly extract the data points you need to conduct more complex analyses.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the cancer vaccine space.
How we target the data for cancer vaccine therapies
We house all publicly available sources of data updated within 24 – 48 hours of publication proactively. Our sources cover (but are not limited to):
- Clinical trials registries
- Scientific journals and publications
- Company reports and presentations
- Press releases
- Conference reports and abstracts
- Government and regulatory organizations
- Newspapers and other media
- Patents
Related content
H1 2024 Cancer Vaccine Landscape Review
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Beacon Cancer Vaccine: 2024 ASCO Annual Meeting Abstracts
What our customers say
Beacon is a great database that people should pay attention to. It's much better than many of the more generic databases that try to capture all data about everything
Director
Top Biotech Company
Our Cancer Vaccine Expert
Gloria Castro is the lead research analyst for Beacon Cancer Vaccine.
Sign up for our weekly newsletter to uncover the latest insights into the Cancer Vaccine landscape using data from Beacon.
Other Beacon Solutions
Covering all Antibody Drug Conjugates (ADCs), Small Molecule Drug Conjugates (SMDCs), Protein Drug Conjugates (PDCs), Immunotoxins and more
Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented Antibodies and more
Covering all engineered and non-engineered immune cell therapies, including CAR-T, TCR, NK, TILs, Gamma-Delta T Cells and more
Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets
Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.
Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.
From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.
Covering all therapeutics aimed at treating immune-mediated diseases – Beacon Immune Tolerance provides drug developers with detailed views of the expanding immune tolerance landscape.
Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.
From capturing viral family and strains to understanding any genetic modifications – Beacon Oncolytic Viruses steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the Oncolytic Virus field.
Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.
Beacon TPD provides the solution you need to master the targeted protein degradation field.
Any questions? Contact us
To learn more about how we can tailor Beacon Cancer Vaccine to help you, get in touch with our sales team
About Beacon
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
